{"product_id":"lipojet-in-vitro-transfection-kit-ver-ii-bht2200001","title":"LipoJet™ In Vitro Transfection Kit (Ver. II)","description":"\u003cdiv class=\"bhp-desc\"\u003e\n\u003cstyle\u003e.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}.bhp-desc p{margin:0 0 12px}.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}.bhp-desc .bhp-figure{margin:16px 0 20px;text-align:center}.bhp-desc .bhp-figure img{max-width:100%;height:auto;display:block;margin:0 auto 6px}.bhp-desc .bhp-figure figcaption{font-size:14px;color:#444;text-align:left;line-height:1.5}.bhp-desc .bhp-data-table th{width:auto}.bhp-desc .bhp-data-table td{font-size:14px}\u003c\/style\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cp\u003eNovel fluorinated cationic lipids form the basis of LipoJet™ Transfection Kit, which is built on SignaGen's innovative, proprietary lipid-conjugation technology. SignaGen presents the kit as the most powerful gene delivery tool available and at the same time a very gentle one, holding significant advantages over competing lipid transfection reagents on the market, and as the more cost-effective option next to leading products there, always giving higher transfection efficiency with less cytotoxicity. Its applications span plasmid DNA, siRNA, or the two together, across most mammalian cell types.\u003c\/p\u003e\n\u003ch2\u003eSpecifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003eTransfection Type\u003c\/th\u003e\n\u003ctd\u003eDNA Transfection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eApplication Setting\u003c\/th\u003e\n\u003ctd\u003eIn Vitro\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePre-Optimized\u003c\/th\u003e\n\u003ctd\u003eNo — General-Purpose Formulation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eStore at 4 °C for LipoJet™ Reagent and RT for LipoJet™ Transfection Buffer (5x). If stored properly, the product is stable for 12 months or longer.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\n\u003ch2\u003eKit Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eLipoJet™ Reagent, 1.0 ml sufficient for 1000 DNA transfections and 1000 siRNA transfections (24-well plate)\u003c\/li\u003e\n\u003cli\u003eLipoJet™ Transfection Buffer (5x), 8.0 mL to make 40 mL of working solution (1x )\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eFeatures\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eVersatile: DNA transfection, siRNA transfection and combined DNA\/siRNA co-transfection\u003c\/li\u003e\n\u003cli\u003ePowerful: outstanding efficiency in adherent cells\u003c\/li\u003e\n\u003cli\u003eExtremely low toxicity: better cell viability following transfection\u003c\/li\u003e\n\u003cli\u003eEconomical: more transfections per unit of reagent\u003c\/li\u003e\n\u003cli\u003eEasy to use: single-tube reaction, compatible with serum\/antibiotics\u003c\/li\u003e\n\u003cli\u003eSuited to high-throughput work\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003ePerformance Data\u003c\/h2\u003e\n\u003cfigure class=\"bhp-figure\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/signagen-LipoJet_Reagent.jpg?v=1790173423\" alt=\"LipoJet™ In Vitro Transfection Kit (Ver. II) – GFP transfection vs other reagents in HeLa, Cos-7, NIH-3T3, CHO and HEK293\" loading=\"lazy\"\u003e\u003cfigcaption\u003eAn efficiency comparison of LipoJet™ reagent vs. brand-name products to transfect HeLa, Cos-7, NIH-3T3, CHO, and HEK293 (left panel) and Cos-7 (right panel). pEGFP-N3 cDNA (0.5 µg\/well of 24-well plate) was transfected into different mammalian cells per the standard transfection protocols in the presence of serum (10% FBS) and antibiotics as recommended by the manufacturers. The transfection efficiency was analyzed via FACS 48 hours post-transfection.\u003c\/figcaption\u003e\u003c\/figure\u003e\u003cfigure class=\"bhp-figure\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/signagen-LipoJet_Cell_Viability.jpg?v=1790173423\" alt=\"LipoJet™ In Vitro Transfection Kit (Ver. II) – HeLa cell viability vs other reagents by MTT assay and phase contrast\" loading=\"lazy\"\u003e\u003cfigcaption\u003eA toxicity comparison of LipoJet™ reagent vs. brand-name products to transfect HeLa cells. pEGFP-N3 cDNA (1.0 µg\/well of 24-well plate) was transfected to HeLa cells per the standard transfection protocols in the presence of serum (10% FBS) and antibiotics as recommended by the manufacturers. The MTT assay (right panel) and phase contrast imaging (left panel) were used to analyze the cell viability 48 hours post-transfection.\u003c\/figcaption\u003e\u003c\/figure\u003e\u003cfigure class=\"bhp-figure\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/signagen-LipoJet_L2K_PolyJet_293T.gif?v=1790173423\" alt=\"LipoJet™ In Vitro Transfection Kit (Ver. II) – GFP transfection in HEK293T cells vs Lipofectamine 2000 and PolyJet™\" loading=\"lazy\"\u003e\u003cfigcaption\u003eA comparison of LipoJet™ reagent vs. Lipofectamine 2000 (L2K) and PolyJet™ transfection reagent on HEK293T cell. pEGFP-N3 cDNA (0.125 µg\/well, 0.25 µg\/well and 0.5 µg\/per well of 24-well plate) was transfected into 293T cells using the standard transfection protocols in presence of serum (10% FBS) with LipoJet™ (upper panel at LipoJet™\/DNA (µl\/µg) ratio=2), L2K (middle panel at L2K\/DNA (µl\/µg) ratio=3) and PolyJet™ (lower panel at at PolyJet™\/DNA (µl\/µg) ratio=3) respectively. The cells were visualized by a Nikon Eclipse Fluorescence microscope 48 hours post-transfection.\u003c\/figcaption\u003e\u003c\/figure\u003e\u003cfigure class=\"bhp-figure\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/signagen-LipoJet_L2K_PolyJet_HELA.gif?v=1790173423\" alt=\"LipoJet™ In Vitro Transfection Kit (Ver. II) – GFP transfection in HeLa cells vs Lipofectamine 2000 and PolyJet™\" loading=\"lazy\"\u003e\u003cfigcaption\u003eA comparison of LipoJet™ reagent vs. Lipofectamine 2000 (L2K) and PolyJet™ transfection reagent on HeLa cells. pEGFP-N3 cDNA (0.125 µg\/well, 0.25 µg\/well and 0.5 µg\/per well of 24-well plate) was transfected into Hela cells using the standard transfection protocols in presence of serum (10% FBS) with LipoJet™ (upper panel at LipoJet™\/DNA (µl\/µg) ratio=2), L2K (middle panel at L2K\/DNA (µl\/µg) ratio=3) and PolyJet™ (lower panel at at PolyJet™\/DNA (µl\/µg) ratio=3) respectively. The cells were visualized by a Nikon Eclipse Fluorescence microscope 48 hours post-transfection.\u003c\/figcaption\u003e\u003c\/figure\u003e\u003cfigure class=\"bhp-figure\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/signagen-LipoJet_HEK_GFP_siRNA.gif?v=1790173423\" alt=\"LipoJet™ In Vitro Transfection Kit (Ver. II) – GFP silencing by DNA\/siRNA co-transfection in HEK293 cells\" loading=\"lazy\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/signagen-LipoJet_Hela_GFP_siRNA.gif?v=1790173423\" alt=\"LipoJet™ In Vitro Transfection Kit (Ver. II) – GFP silencing by DNA\/siRNA co-transfection in HeLa cells\" loading=\"lazy\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/signagen-LipoJet_SAOS_GFP_siRNA.gif?v=1790173423\" alt=\"LipoJet™ In Vitro Transfection Kit (Ver. II) – GFP silencing by DNA\/siRNA co-transfection in SaoS-2 cells\" loading=\"lazy\"\u003e\u003cfigcaption\u003eExceptional gene silencing of LipoJet™ reagent during DNA\/siRNA co-transfection on mammalian cells. Transfection of GFP cDNA (left panel, 0.25 µg per well of 24-well plate) and co-transfection of GFP cDNA ( 0.25 µg per well of 24-well plate) and GFP targeted siRNA (final 10 nM, right panel) with LipoJet™ reagent leads to exceptional gene silencing on HEK293 (upper panel), Hela (middle panel) and SaoS-2 (lower panel) cells respectively. The cells were visualized by a Nikon Eclipse Fluorescence microscope 48 hours post-transfection.\u003c\/figcaption\u003e\u003c\/figure\u003e\u003cfigure class=\"bhp-figure\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/signagen-LipoJet_HUVEC_mCherry-FITC-siRNA.jpg?v=1790173423\" alt=\"LipoJet™ In Vitro Transfection Kit (Ver. II) – mCherry DNA and FITC-siRNA co-transfection in HUVEC\" loading=\"lazy\"\u003e\u003cfigcaption\u003eExceptional DNA\/siRNA co-transfection efficiency on HUVEC. Co-transfection of mCherry cDNA (0.10 µg per well of 24-well plate) and FITC-conjugated siRNA (final 30 nM per well of 24-well plate) to HUVEC with LipoJet™ reagent gave rise to 60% mCherry+ (phase contrast overlapped with mCherry imaging, left panel) and nearly 100% FITC-siRNA+ (phase contrast overlapped with FITC imaging, right panel) HUVEC 24 hours after transfection. The pictures were given by Dr. Pan Kong of USC as a courtesy.\u003c\/figcaption\u003e\u003c\/figure\u003e\u003cfigure class=\"bhp-figure\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/signagen-LipoJet_HEK293_EG5_siRNA.gif?v=1790173423\" alt=\"LipoJet™ In Vitro Transfection Kit (Ver. II) – KIF11 (EG5) siRNA knockdown causing cell rounding in HEK293 cells\" loading=\"lazy\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/signagen-LipoJet_Hela_EG5_siRNA.gif?v=1790173423\" alt=\"LipoJet™ In Vitro Transfection Kit (Ver. II) – KIF11 (EG5) siRNA knockdown causing cell rounding in HeLa cells\" loading=\"lazy\"\u003e\u003cfigcaption\u003eExcellent silencing of endogenously expressed KIF11 (also known as EG5) in HEK293 (upper panel) and HeLa (lower panel) cells with LipoJet™ reagent at 10 nM EG5 siRNA. KIF11 (also known as EG5) encodes a motor protein that belongs to the kinesin-like protein family involved in chromosome positioning and bipolar spindle formation during cell mitosis. A reduction in KIF11 levels causes mitotic arrest. LipoJet™ reagent effectively delivers EG5 siRNA (final 10 nM) to HEK293 and HeLa cells, leading to more than 80% of “round-up” phenotype of HEK293 and HeLa cells 24h post-transfection over negative control (final 10 nM with sham EG5 siRNA). The phenotype of “rounded-up” HEK293 and HeLa cells was visualized 24h post-transfection with a Nikon microscope.\u003c\/figcaption\u003e\u003c\/figure\u003e\u003cfigure class=\"bhp-figure\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/signagen-LipoJet_hESCs.jpg?v=1790173423\" alt=\"LipoJet™ In Vitro Transfection Kit (Ver. II) – GFP transfection in human embryonic stem cells (hESCs), DIC and fluorescence\" loading=\"lazy\"\u003e\u003cfigcaption\u003eAn image showing the exceptional transfection efficiency of LipoJet™ Transfection Kit on Human embryonic stem cells (hESCs). The hESCs grown in E8 medium on Geltrexvs (left panel, DIC imaging) were transfected with pEF1α-GFP. The GFP expression (right panel) was visualized by Nikon Eclipse Fluorescence microscope 24 hours post-transfection. The above pictures were provided by Dr. Marina Pryzhkova of Johns Hopkins University as a courtesy\u003c\/figcaption\u003e\u003c\/figure\u003e\u003ch3\u003eTransfection Efficiency by Cell Line\u003c\/h3\u003e\n\u003ctable class=\"bhp-spec-table bhp-data-table\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCell Line\u003c\/th\u003e\n\u003cth\u003eDNA Transfection Efficiency\u003c\/th\u003e\n\u003cth\u003esiRNA Transfection Efficiency\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e293, 293T\u003c\/td\u003e\n\u003ctd\u003e85%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3T3, NIH 3T3\u003c\/td\u003e\n\u003ctd\u003e65%\u003c\/td\u003e\n\u003ctd\u003e90% at 20 nM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3T3-L1\u003c\/td\u003e\n\u003ctd\u003e30%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eA549\u003c\/td\u003e\n\u003ctd\u003e80%\u003c\/td\u003e\n\u003ctd\u003e90% at 10 nM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eB16-F10\u003c\/td\u003e\n\u003ctd\u003e75%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBNLCL.2\u003c\/td\u003e\n\u003ctd\u003e55%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eC2C12\u003c\/td\u003e\n\u003ctd\u003e80%\u003c\/td\u003e\n\u003ctd\u003e90% at 10 nM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eC3H\/10T1\/2\u003c\/td\u003e\n\u003ctd\u003e60%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCaco-2\u003c\/td\u003e\n\u003ctd\u003e20%\u003c\/td\u003e\n\u003ctd\u003e80 % at 20 nM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRat primary cardiomyocytes\u003c\/td\u003e\n\u003ctd\u003e10%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCHO\u003c\/td\u003e\n\u003ctd\u003e80%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOS1\u003c\/td\u003e\n\u003ctd\u003e70%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOS7\u003c\/td\u003e\n\u003ctd\u003e75%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHuman bladder carcinomal cell\u003c\/td\u003e\n\u003ctd\u003e80%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003emES\u003c\/td\u003e\n\u003ctd\u003e50%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eiMEF\u003c\/td\u003e\n\u003ctd\u003e55%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHBEC\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCT116\u003c\/td\u003e\n\u003ctd\u003e75%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHela\u003c\/td\u003e\n\u003ctd\u003e80%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHepG2\u003c\/td\u003e\n\u003ctd\u003e60%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHT-29\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHuH-7\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLNCaP\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMC3T3-E1\u003c\/td\u003e\n\u003ctd\u003e50%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMCF10A\u003c\/td\u003e\n\u003ctd\u003e40%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMCF7\u003c\/td\u003e\n\u003ctd\u003e50%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMDA-MB-231\u003c\/td\u003e\n\u003ctd\u003e50%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMDCK\u003c\/td\u003e\n\u003ctd\u003e20%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMEF\u003c\/td\u003e\n\u003ctd\u003e50%\u003c\/td\u003e\n\u003ctd\u003e85% at 30 nM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHuman primary melanocytes\u003c\/td\u003e\n\u003ctd\u003e50%\u003c\/td\u003e\n\u003ctd\u003e85% at 30 nM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHuman primary melanoma\u003c\/td\u003e\n\u003ctd\u003e50%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHuman immortalized microglial\u003c\/td\u003e\n\u003ctd\u003e50%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003emIMCD-3\u003c\/td\u003e\n\u003ctd\u003e50%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMRC-5\u003c\/td\u003e\n\u003ctd\u003e50%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eN2A\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePC3\u003c\/td\u003e\n\u003ctd\u003e70%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRAW 264.7\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRPE\u003c\/td\u003e\n\u003ctd\u003e30%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSH-SY-5Y\u003c\/td\u003e\n\u003ctd\u003e75%\u003c\/td\u003e\n\u003ctd\u003e90% at 25 nM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSK-OV-3\u003c\/td\u003e\n\u003ctd\u003e70%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU-2OS\u003c\/td\u003e\n\u003ctd\u003e80%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVERO\u003c\/td\u003e\n\u003ctd\u003e40%\u003c\/td\u003e\n\u003ctd\u003e–\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ehESCs\u003c\/td\u003e\n\u003ctd\u003e70%\u003c\/td\u003e\n\u003ctd\u003e90% at 40 nM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2\u003eApplications\u003c\/h2\u003e\n\u003cp\u003eThis DNA transfection reagent supports a range of molecular biology applications including transient and stable transfection, reporter assays, protein expression studies, and gene function analysis in mammalian cell systems.\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cstrong\u003eFor Research Use Only (RUO)\u003c\/strong\u003e — Not for diagnostic or therapeutic use. Handle reagents according to institutional biosafety guidelines. Refer to the Safety Data Sheet (SDS) for detailed handling and disposal instructions.\u003c\/div\u003e\n\u003c\/div\u003e","brand":"SignaGen Laboratories","offers":[{"title":"0.1 mL","offer_id":54042899054957,"sku":"SL100468-0P1ML","price":40.0,"currency_code":"USD","in_stock":true},{"title":"0.5 mL","offer_id":54042901086573,"sku":"SL100468-0P5ML","price":208.0,"currency_code":"USD","in_stock":true},{"title":"1.0 mL","offer_id":54042901119341,"sku":"SL100468-1P0ML","price":388.0,"currency_code":"USD","in_stock":true},{"title":"1.0 mL x 5","offer_id":54042901152109,"sku":"SL100468-1P0MLX5","price":1843.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/signagen-LipoJet_L2K_PolyJet_293T_1e127633-5463-48d7-9175-5f831548b0d2.gif?v=1790175945","url":"https:\/\/www.ebiohippo.com\/products\/lipojet-in-vitro-transfection-kit-ver-ii-bht2200001","provider":"BioHippo","version":"1.0","type":"link"}